MTX

Revive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19

Retrieved on: 
Lundi, avril 18, 2022
CSE, Patient, Rituximab, TNF inhibitor, MMF, TNF, CNI, Research, RVV, Modern Rheumatology, Rheumatology, Vaccine, Therapy, Abatacept, GLOBE, MTX, Cyclophosphamide, Methotrexate, Sulfasalazine, Disorder, Severe acute respiratory syndrome coronavirus 2, Pharmaceutical industry, Fertilizer, Bucillamine

The newly published study further validates the potential of Bucillamine in the treatment course for COVID-19.

Key Points: 
  • The newly published study further validates the potential of Bucillamine in the treatment course for COVID-19.
  • The potential of Bucillamine for COVID-19 is evident with its anti-inflammatory and antiviral properties and its potential use in patients who have taken SARS-CoV-2 mRNA vaccines, said Michael Frank, CEO of Revive.
  • Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19.
  • With its acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders.

Minerals Technologies Announces First Quarter 2022 Conference Call

Retrieved on: 
Lundi, avril 11, 2022
Conference call, GLOBE, NYSE, Company, Mineral, MTI, Steel, MTX, Webcast, Conference, Online shopping

NEW YORK, April 11, 2022 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) (MTI or the Company) announced today that it will release results for its first quarter ended April 3, 2022 on Thursday, April 28, 2022 after the market close.

Key Points: 
  • NEW YORK, April 11, 2022 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) (MTI or the Company) announced today that it will release results for its first quarter ended April 3, 2022 on Thursday, April 28, 2022 after the market close.
  • The Company will host a conference call on Friday, April 29, 2022 at 11:00 a.m. Eastern Time to discuss these results.
  • The conference call will be webcast and can be accessed at Minerals Technologies website at www.mineralstech.com .
  • To listen to the call, go to the MTI website and click on "Investor Relations," then click on "Quarterly Results & Conference Calls."

VAPORESSO Kicks off Rebranding at VAPEXPO with New Logo Reveal

Retrieved on: 
Lundi, avril 11, 2022
Letter, ENDS, CMO, MTX, Love, FIT, New, Technology, Hope, GTI, GLOBE, GEN, Herbal cigarette, Video game console

World-renowned vaping brand VAPORESSO kicked off its rebranding campaign with the reveal of a new logo.

Key Points: 
  • World-renowned vaping brand VAPORESSO kicked off its rebranding campaign with the reveal of a new logo.
  • VAPORESSOs new logo features the letter V at the forefront, encircled behind by the letter O.
  • The reveal of VAPORESSOs new logo comes as part of a shift in brand identity, which will be unveiled in the coming month.
  • In the future, VAPORESSO plans on continuing to expand its 4S stores to Paris and other major French cities.

Jyseleca® approved in Japan for ulcerative colitis

Retrieved on: 
Lundi, mars 28, 2022
Contraindication, EA, CET, Euronext, NASDAQ, Adult, Tablet, MTX, MHLW, Ulcerative colitis, Disease-modifying antirheumatic drug, Ministry of Health, Labour and Welfare, Medicine, Gilead Sciences, Safety, Rheumatoid arthritis, Interview, Inflammation, JAK1, Methotrexate, UC, Gilead, Physician, Product, Union, Degenerative disease, Fibrosis, Galapagos NV, Maintenance, RA, Eisai, European, Patient, Disease, Pharmaceutical industry, Health, Filgotinib

(Tokyo, Japan), Eisai Co., Ltd. (Tokyo, Japan) and EA Pharma Co., Ltd. (Tokyo, Japan) today announced the approval by the Japanese Ministry of Health, Labour and Welfare (MHLW), of a second indication for Jyseleca (filgotinib), a once-daily, oral, JAK1 preferential inhibitor, for the treatment of patients with moderate-to-severe active ulcerative colitis (UC).

Key Points: 
  • (Tokyo, Japan), Eisai Co., Ltd. (Tokyo, Japan) and EA Pharma Co., Ltd. (Tokyo, Japan) today announced the approval by the Japanese Ministry of Health, Labour and Welfare (MHLW), of a second indication for Jyseleca (filgotinib), a once-daily, oral, JAK1 preferential inhibitor, for the treatment of patients with moderate-to-severe active ulcerative colitis (UC).
  • The approval of this second indication for Jyseleca in Japan is based on data from the randomized, double-blind, placebo-controlled phase 2b/3 SELECTION study.
  • Jyseleca was approved in Japan in September 2020 for the treatment of rheumatoid arthritis (RA), including the prevention of structural joint damage, in patients who had inadequate response to conventional therapies.
  • Gilead Japan will hold the marketing authorization of Jyseleca in Japan and will be responsible for product supply.

MTX Group Launches 988 Crisis SafeResponse to Help Agencies Adapt to Upcoming 988 Hotline Mandate

Retrieved on: 
Jeudi, mars 24, 2022
Organization, Public sector, National Suicide Prevention Lifeline, Mental health, Multimedia, MTX, Health, Government, View, COVID-19, List of life sciences, AI, Happiness, Medicine

FRISCO, Texas, March 23, 2022 /PRNewswire/ -- MTX Group (MTX) , a global technology consulting firm, officially launched MTX 988 Crisis SafeResponse (SafeResponse), enabling public sector agencies to assist individuals facing mental health issues to receive the immediate help they need.

Key Points: 
  • FRISCO, Texas, March 23, 2022 /PRNewswire/ -- MTX Group (MTX) , a global technology consulting firm, officially launched MTX 988 Crisis SafeResponse (SafeResponse), enabling public sector agencies to assist individuals facing mental health issues to receive the immediate help they need.
  • MTX Group launches 988 Crisis SafeResponse enabling agencies to assist those facing mental health issues.
  • "By supporting agencies and the communities they serve through SafeResponse, we can help deliver life-saving assistance to those in mental health emergencies."
  • To learn more about MTX 988 Crisis SafeResponse, visit the solution's webpage , watch this video or contact [email protected] .

Memo Therapeutics AG Closes Series B Financing at CHF37 Million Following Oversubscribed CHF23 Million Extension

Retrieved on: 
Mercredi, février 16, 2022
Biotechnology, Pharmaceutical, Health, Patient, Inhalation, CMV, Cytomegalovirus, Infection, Efficiency, Neutralizing antibody, Basler Kantonalbank, BK, BK virus, Therapy, Antibody, Swiss Federal Laboratories for Materials Science and Technology, MTX, Mining, Severe acute respiratory syndrome coronavirus 2, COVID-19, Pharmaceutical industry, Vaccine, Medical device, Investment

In addition, MTx will use the funding to develop and expand its antibody pipeline and secure new partnering agreements.

Key Points: 
  • In addition, MTx will use the funding to develop and expand its antibody pipeline and secure new partnering agreements.
  • This progress has resonated with highly renowned strategic and financial investors, who we are happy to welcome in this oversubscribed extension of our Series B, said Dr. Karsten Fischer, Chief Executive Officer of Memo Therapeutics AG.
  • Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis.
  • Exploiting the power of its microfluidic single-cell molecular cloning and screening technologies, Memo Therapeutics AG engages in antibody discovery across species and indications for proprietary and partnered projects.

Minerals Technologies Declares Quarterly Dividend

Retrieved on: 
Mercredi, janvier 26, 2022
MTX, Steel, MTI, NYSE, GLOBE, Holding company, Lithium

NEW YORK, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) today declared a regular quarterly dividend of $0.05 per share on the Companys common stock.

Key Points: 
  • NEW YORK, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) today declared a regular quarterly dividend of $0.05 per share on the Companys common stock.
  • The dividend is payable on March 10, 2022 to stockholders of record on February 17, 2022.
  • New York-basedMinerals Technologies Inc. (MTI)is a global resource- and technology-based company that develops, produces and markets a broad range of specialty mineral, mineral-based and synthetic mineral products and related systems and services.
  • MTI serves the paper, foundry, steel, construction, environmental, energy, polymer and consumer products industries.

Minerals Technologies Announces Fourth Quarter 2021 Conference Call

Retrieved on: 
Lundi, janvier 17, 2022
Webcast, Conference call, NYSE, MTX, MTI, Conference, Mineral, Company, GLOBE, Steel

NEW YORK, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) (MTI or the Company) announced today that it will release results for its fourth quarter ended December 31, 2021 on Thursday, February 3, 2022 after the market close.

Key Points: 
  • NEW YORK, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) (MTI or the Company) announced today that it will release results for its fourth quarter ended December 31, 2021 on Thursday, February 3, 2022 after the market close.
  • The Company will host a conference call on Friday, February 4, 2022 at 11:00 a.m. Eastern Time to discuss these results.
  • The conference call will be webcast and can be accessed at Minerals Technologies website at www.mineralstech.com .
  • To listen to the call, go to the MTI website and click on "Investor Relations," then click on "Quarterly Results & Conference Calls."

SERB receives EU approval for Voraxaze® (glucarpidase) as Rescue Therapy for High Dose Methotrexate Toxicity

Retrieved on: 
Vendredi, janvier 14, 2022
Ageing, Patient, Osteosarcoma, Leukemia, Lymphoma, Kidney, Liver, Union, Degenerative disease, SERB, Plasma, GLOBE, Recurrence, Marketing, Royal commission, Risk, Cancer, CHMP, Toxicity, European Commission, MTX, FDA, BTG, European Medicines Agency, Pharmaceutical industry, EU

Voraxaze is now authorized for marketing in all members states of the European Union as well as Iceland, Liechtenstein, and Norway.

Key Points: 
  • Voraxaze is now authorized for marketing in all members states of the European Union as well as Iceland, Liechtenstein, and Norway.
  • It will be sold in these markets by SERB, which merged with BTG Specialty Pharmaceuticals in March 2021.
  • The efficacy of Voraxaze has been evaluated in four open-label multi-center studies in patients with delayed methotrexate elimination due to renal dysfunction.
  • In 169 patients with methotrexate concentrations measured by chromatographic methods, a median reduction of > 98% in methotrexate concentration occurred within 15 minutes following Voraxaze administration.

Theramex Announces an Agreement with Enzene Biosciences Limited for the Development and Commercialisation of Tocilizumab, a Biosimilar for the Treatment of Rheumatoid Arthritis

Retrieved on: 
Jeudi, décembre 23, 2021
Biotechnology, Pharmaceutical, Health, Other Health, Giant, Laboratory, Tocilizumab, Alkem Laboratories, CAR, Patient, Pain, Methotrexate, Joint, Fatigue, CMO, Swelling, RA, Giant cell arteritis, Fertility, Birth, Flare, Adult, Disease-modifying antirheumatic drug, Giant cell, Rheumatoid arthritis, Man, Health, Solution, Bone, MTX, CDMO, Osteoporosis, Woman, Nonsteroidal anti-inflammatory drug, CRS, Partnership, Menopause, Fine chemical, Pharmaceutical industry, Theramex, Rheumatology, Theramex, Enzene Biosciences Ltd., THERAMEX, ENZENE BIOSCIENCES LTD.

Tocilizumab, in combination with Methotrexate (MTX), is indicated for the treatment of rheumatoid arthritis.

Key Points: 
  • Tocilizumab, in combination with Methotrexate (MTX), is indicated for the treatment of rheumatoid arthritis.
  • Rheumatoid arthritis is a chronic condition that causes pain, swelling and stiffness in the joints.
  • Some people with rheumatoid arthritis also experience problems in other parts of the body, or more general symptoms such as tiredness and weight loss1.
  • For more information on Enzene Biosciences Ltd., please visit www.enzene.com
    For more information on Alkem Laboratories Ltd., please visit www.alkemlabs.com